¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× °Ç¸ÁÁõ °æµµ ÀÎÁöÀå¾ÖÀÇ Àν¶¸° ºñ°­Åõ¿©: ü°èÀû ¹®Çå °íÂû ¹× ¸ÞŸºÐ¼®
Intranasal Insulin for Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Systematic Review and Meta-analysis

Çѱ¹ÀÓ»ó¾àÇÐȸÁö 2017³â 27±Ç 3È£ p.161 ~ p.170

»ç¶ó ¾Ë¶óÀÚ¸£(Sarah Alnajjar) - ÀÌÈ­¿©ÀÚ´ëÇб³ ´ëÇпø »ý¸í¾àÇкÎ
ÁøÇý°æ(Jin Hye-Kyung) - ÀÌÈ­¿©ÀÚ´ëÇб³ ´ëÇпø ¾àÇаú
°­ÁöÀº(Kang Ji-Eun) - ÀÌÈ­¿©ÀÚ´ëÇб³ ´ëÇпø »ý¸í¾àÇкÎ
¹Ú¼ÒÇö(Park So-Hyun) - ÀÌÈ­¿©ÀÚ´ëÇб³ ´ëÇпø »ý¸í¾àÇкÎ
ÀÌÁ¤¿¬(Rhie Sandy Jeong) - ÀÌÈ­¿©ÀÚ´ëÇб³ ´ëÇпø »ý¸í¾àÇкÎ

Abstract

Background: There is recent evidence that insulin resistance is responsible for increasing the risk of developing cognitive dysfunction. To systematically review the influence of intranasal insulin treatment on the cognitive function in Alzheimer¡¯s disease patients.

Methods: Randomized controlled trials comparing the cognitive effects of intranasal insulin therapy in Alzheimer¡¯s disease patients with controlled interventions were retrieved from Pubmed, Medline, Embase and Cochrane library. Meta-analysis was conducted on the cognitive measurements with a subgroup analysis by dose, gender and apolipoprotein E allele 4 (ApoE ¥å4) status.

Results: Seven randomized controlled trials were eligible for inclusion. Intranasal insulin had a positive influence on the cognitive function as compared to placebo without a statistical significance (standardized mean difference; SMD = 0.109; 95% confidence interval; CI -0.04 to 0.26; P=0.14). In subgroup analysis, a 20 IU dose of intranasal insulin induced a significant improvement in cognitive function (SMD = 0.14; 95% CI 0.05 to 0.24; P=0.004), but 40 IU did not show this effect (SMD = -0.01; 95% CI -0.11 to 0.09; P=0.82). ApoE ¥å4 positive patients showed a significant decline in cognitive function as compared to ApoE ¥å4 positive patients in the control group (SMD = -0.213; 95% CI -0.38 to -0.04; P=0.015). Such an effect was not apparent in ApoE ¥å4 negative patients. Gender had no influence on the cognitive outcomes.

Conclusion: The results indicate that intranasal insulin may have beneficial effect in improving the cognitive function in Alzheimer¡¯s disease patients.

Å°¿öµå

Alzheimer¡¯s disease, intranasal insulin, systematic review, meta-analysis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
intranasal insulin may have beneficial effect in improving the cognitive function in Alzheimer¡¯s disease patients
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå